Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257

Ighovwerha Ofotokun*, Lumine H. Na, Raphael J. Landovitz, Heather J. Ribaudo, Grace A. Mccomsey, Catherine Godfrey, Francesca Aweeka, Susan E. Cohn, Manish Sagar, Daniel R. Kuritzkes, Todd T. Brown, Kristine B. Patterson, Michael F. Para, Randi Y. Leavitt, Angelina Villasis-Keever, Bryan P. Baugh, Jeffrey L. Lennox, Judith S. Currier

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience